Hafion Inc.
Ann Arbor, MI Doing business as Hafion Hafion Inc.
- UEI
- G41ASXW94LC5
- CAGE
- 7RP26
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 1505 Hillridge Blvd, Ann Arbor, MI 48103, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Formulation of a prophylactic vaccine against pseudomonas aeruginosa - summary pseudomonas aeruginosa (PA) is an… | National Institute of Allergy and Infectious Diseases | $1,499,996 | |
| Production of a nanoparticle vaccine to aid in smoking cessation | National Institute on Drug Abuse | $606,090 | |
| Toward the development of a protein: non-protein macromolecular adjuvants. | National Institute of Allergy and Infectious Diseases | $310,592 | |
| Determination of protective efficacy of multimeric shigella vaccine as the next step toward human trials | National Institute of Allergy and Infectious Diseases | $178,033 | |
| Generating synergy between protein and non-protein macromolecular adjuvants | National Institute of Allergy and Infectious Diseases | $224,992 |
About Hafion Inc.
Hafion Inc., registered as a corporate entity doing business as Hafion, provides goods and services to the U.S. federal government through contract and grant awards. Hafion is a self-certified small disadvantaged business and a woman-owned small business.
Through prime federal contract awards, Hafion has provided research and development services related to protein and macromolecular adjuvants for vaccines. This includes a $310,592 definitive contract with the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to develop protein:non-protein macromolecular adjuvants. The contract was set aside for small businesses and completed in August 2021.
Through prime and sub federal grants, Hafion has provided research and development services related to vaccines, including formulation of a prophylactic vaccine against Pseudomonas Aeruginosa. This includes a $1,199,997 project grant from the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to formulate a vaccine against Pseudomonas Aeruginosa to prevent initial colonization and protect vulnerable patients. Hafion has also received subawards to produce adjuvants and provide conjugation and biophysical characterization services in support of University of Missouri grants for the development of fusion protein vaccines.
Quick answers
What is Hafion Inc.'s UEI?
Hafion Inc.'s Unique Entity ID (UEI) in SAM.gov is G41ASXW94LC5.
What is Hafion Inc.'s CAGE code?
Hafion Inc.'s CAGE code is 7RP26.
What is Hafion Inc.'s primary NAICS code?
Hafion Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Hafion Inc. located?
Hafion Inc.'s physical address in SAM.gov is 1505 Hillridge Blvd, Ann Arbor, MI 48103, USA.
Is Hafion Inc. registered in SAM.gov?
Yes. Hafion Inc.'s SAM.gov registration is active through April 21, 2027.
What is Hafion Inc.'s most recent federal award?
Hafion Inc.'s most recent federal grant award is Formulation of a prophylactic vaccine against pseudomonas aeruginosa - summary pseudomonas aeruginosa (PA) is an… (R43AI167091), from National Institute of Allergy and Infectious Diseases, on March 16, 2022.
On GovTribe
See Hafion Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors